January/February 2017

Cost-Effectiveness of Extended-Release Carbidopa-Levodopa for Advanced Parkinson's Disease

February 21, 2017

Original Research

Existing levodopa therapies for Parkinson’s disease often provide inadequate symptom control after prolonged treatment. This study assessed the cost-effectiveness of an extended-release carbidopa-levodopa formulation (IPX066).

The Value of Vaccination: Myth vs Evidence in the New Administration

February 21, 2017

From the Editor

In our quest to identify the areas and activities that show the greatest positive impact and value in care and outcomes, we must aim to not let good science and evidence get away from us, particularly when considering vaccination.